Search Result
Results for "
contractility
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
8
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B1793
-
|
|
Potassium Channel
|
Neurological Disease
Cancer
|
|
Tetraethylammonium chloride is a non-selective potassium channel blocker. Tetraethylammonium chloride is a good substrate for organic cation transporter (OCTN1). Tetraethylammonium chloride antitumor properties .
|
-
-
- HY-B0763
-
Ibudilast
Maximum Cited Publications
10 Publications Verification
KC-404; AV-411; MN-166
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
Cancer
|
|
Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
|
-
-
- HY-111098
-
|
|
TRP Channel
|
Cardiovascular Disease
|
|
GSK1702934A is a selective TRPC3 agonist. GSK1702934A modulates cardiac contractility and f arrhythmogenesis by activation of TRPC3 .
|
-
-
- HY-W016733
-
|
H-D-Cit-OH
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
D-Citrulline (H-D-Cit-OH) is a stereoisomer of L-citrulline (HY-N0391). D-Citrulline significantly attenuates polymorphonuclear leukocyte (PMN)-induced cardiac contractile dysfunction in the isolated perfused rat heart subjected to ischemia/reperfusion via a non-NO-mediated mechanism .
|
-
-
- HY-W008820
-
|
|
MOFs
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .
|
-
-
- HY-W050000
-
OR-1855
1 Publications Verification
|
Drug Metabolite
Reactive Oxygen Species (ROS)
ERK
p38 MAPK
|
Cardiovascular Disease
Inflammation/Immunology
|
|
OR-1855, an active metabolite of Levosimendan (HY-14286), has effect on myometrial contractility. OR-1855 exerts anti-inflammatory effects by inhibiting IL-1β-induced ROS formation and NAD(P)H oxidase-dependent superoxide radical generation in HUVECs. OR-1855 inhibits IL-1β-induced phosphorylation p38 MAPK, ERK1/2, c-Jun and JNK in HUVECs. OR-1855 can be used for the study of inflammation .
|
-
-
- HY-106844A
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
(+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca 2+ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function .
|
-
-
- HY-136933
-
|
|
Na+/K+ ATPase
|
Cardiovascular Disease
|
|
Gitoxin is a degradation metabolite of Digitoxin (HY-B1357) and a non-competitive Na +/K +-ATPase inhibitor, with an IC50 of 1.18e-6 M against the porcine high-affinity subtype and an IC50 of 2.85e-5 M against the porcine low-affinity subtype. Gitoxin regulates atrial contractility and rhythmicity. Gitoxin is applicable to research related to congestive heart failure .
|
-
-
- HY-100634
-
|
(±)-4-hydroxy Propranolol hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
4-Hydroxypropranolol hydrochloride is a non-cardiac selective β-adrenergic receptor antagonist and a metabolite produced after oral administration of Propranolol (HY-B0573B). 4-Hydroxypropranolol hydrochloride also acts as a membrane stabilizer and possesses intrinsic sympathomimetic inhibitory activity. 4-Hydroxypropranolol hydrochloride blocks β-adrenergic receptors to antagonize the effects of catecholamines, acts as a partial β-adrenergic receptor agonist, and induces membrane stabilization. 4-Hydroxypropranolol hydrochloride alters heart rate, left ventricular contractility, and atrioventricular conduction time. 4-Hydroxypropranolol hydrochloride can be used in research related to cardiovascular and cerebrovascular diseases .
|
-
-
- HY-121467
-
|
Z-338 free base; YM443 free base
|
Cholinesterase (ChE)
|
Metabolic Disease
Inflammation/Immunology
|
|
Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
|
-
-
- HY-147292
-
|
CK-136
|
Calcium Channel
|
Cardiovascular Disease
|
|
Nelutroctiv (CK-136) is an orally active and selective cardiac troponin activator. Nelutroctiv activates cardiac sarcomeres by enhancing the sensitivity of troponin to calcium ions and promoting the interaction between actin and myosin. Nelutroctiv enhances cardiac contractility. Nelutroctiv can be used in the researches for cardiovascular diseases with impaired cardiac contractile function .
|
-
-
- HY-119926
-
|
Hydroxylupanine
|
Integrin
|
Cardiovascular Disease
Neurological Disease
|
|
13-Hydroxylupanine (Hydroxylupanine) is the typical alkaloid profile of sweet lupins.13-Hydroxylupanine blocks ganglionic transmission, decreases cardiac contractility and contracts uterine smooth muscle .
|
-
-
- HY-101366
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
A-61603 is a selective α1A/α1a-adrenergic receptor agonist with Ki of 8.89 nM for rat submaxillary gland α1A, Ki of 30.5 nM for cloned bovine α1a. A-61603 potentiates Ca 2+ transients with EC50 of 6.9 nM. A-61603 stimulates phosphoinositide hydrolysis, induces contractile responses in vas deferens, prostate strips, and spleen strips, and exhibits low activity in aortic rings. A-61603 can be used for research on adrenergic function .
|
-
-
- HY-W008820S
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d6 is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .
|
-
-
- HY-B1233
-
|
2-Amino-6-methylheptane; 1,5-Dimethylhexylamine; 6-Methyl-2-heptylamine
|
Dopamine Receptor
|
Others
|
|
Octodrine (2-Amino-6-methylheptane) is a central nervous stimulant that increases the uptake of dopamine and noradrenaline. Octodrine is found to increase the pain threshold, cardiac rate (positive chronotropic effect) and myocardial contractility (positive inotropic effect) .
|
-
-
- HY-123068
-
|
SQ 14551
|
Drug Derivative
|
Cardiovascular Disease
|
|
Captopril disulfide (SQ 14551) is an orally active disulfide dimer prodrug. Captopril disulfide is metabolized to Captopril and acts as a Bradykinin potentiator. Captopril disulfide enhances the vasodilatory effect of Bradykinin in anesthetized rats and the contractile response of isolated guinea pig ileum to Bradykinin. Captopril disulfide exhibits antihypertensive activity in spontaneously hypertensive rats. Captopril disulfide can be used in hypertension-related research .
|
-
-
- HY-153977
-
|
|
NADPH Oxidase
|
Cardiovascular Disease
|
|
GLX481304 is a specific inhibitor of Nox-2 and -4, with IC50s of 1.25 μM. GLX481304 suppresses ROS production in isolated mouse cardiomyocytes and improves cardiomyocyte contractility. GLX481304 can be used for research of ischemic injury to the heart .
|
-
-
- HY-118960
-
|
|
ATP Synthase
|
Cardiovascular Disease
|
|
BMS-199264 hydrochloride is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 hydrochloride selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 hydrochloride also enhances the recovery of contractile function following reperfusion .
|
-
-
- HY-162345
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
CK-963 is an activator for cardiac troponin (cTnC) with Ki of 11.5 μM. CK-963 exhibits activity in enhancing cardiac contractility in Sprague-Dawley rats .
|
-
-
- HY-P10655
-
|
|
Proton Pump
Calcium Channel
|
Cardiovascular Disease
|
|
Caloxin 1C2 is a specific PMCA (plasma-membrane Ca 2+-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The Ki values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca 2+ transfer. Caloxin 1C2 affects coronary contractility .
|
-
-
- HY-B2155
-
|
|
Cholinesterase (ChE)
|
Metabolic Disease
Inflammation/Immunology
|
|
Acotiamide monohydrochloride trihydrate is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC50 of 1.79 μM. Acotiamide monohydrochloride trihydrate can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide monohydrochloride trihydrate has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
|
-
-
- HY-103291
-
|
|
Bradykinin Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Sar-[D-Phe8]-des-Arg9-Bradykinin is a agonist of B1 receptor. Sar-[D-Phe8]-des-Arg9-Bradykinin selectively amplifies the contractile response when incubation with human recombinant interleukin-1 β (IL-1 β) in rabbit aortic rings .
|
-
-
- HY-N9141
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
Nantenine is a serotonergic receptor antagonist. Nantenine selectively inhibits the contractile response of tissues to serotonin. Nantenine can be isolated from Nandina domestica .
|
-
-
- HY-112071
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Prenalterol is a selective β1-adrenergic receptor agonist. Prenalterol has no effect on gut smooth muscle contractile activity. Prenalterol can be used for researching cardiovascular disease .
|
-
-
- HY-108991
-
|
(-)-T-0509
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
T-0509 ((-)-T-0509) is a selective full agonist of the β1 receptor. T-0509 activates the cAMP signaling pathway through the β1 receptor and enhances myocardial contractility .
|
-
-
- HY-B1233A
-
|
2-Amino-6-methylheptane hydrochloride; 1,5-Dimethylhexylamine hydrochloride; 6-Methyl-2-heptylamine hydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
|
Octodrine (2-Amino-6-methylheptane) is a central nervous activator that increases the uptake of dopamine and noradrenaline. Octodrine is found to increase the pain threshold, cardiac rate (positive chronotropic effect) and myocardial contractility (positive inotropic effect) .
|
-
-
- HY-P4678
-
|
|
Vasopressin Receptor
|
Neurological Disease
|
|
(Phe2,Orn8)-Oxytocin is a selective V1 vasopressin agonist. (Phe2,Orn8)-Oxytocin induces a sustained contractility of rabbit epididymis with EC50 value of 280 nM .
|
-
-
- HY-121467A
-
|
Z-338; YM443
|
Cholinesterase (ChE)
|
Others
Metabolic Disease
Inflammation/Immunology
|
|
Acotiamide hydrochloride is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide hydrochloride can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide hydrochloride has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
|
-
-
- HY-123268A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Ro 363 hydrochloride, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. Ro 363 hydrochloride is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility .
|
-
-
- HY-123268
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Ro 363, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. RO 363 is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility .
|
-
-
- HY-106844
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
EMD 53998 is a cardiotonic agent that increases myocardial contractility as an inhibitor for phosphodiesterase III (PDE III) and a calcium sensitizer. EMD 53998 increases myocardial contractility, reduces energy consumption and the risk of inducing arrhythmias .
|
-
-
- HY-P3591
-
-
-
- HY-107645
-
|
|
mAChR
|
Neurological Disease
|
|
DAU 5884 hydrochloride is a potent muscarinic M3 receptor antagonist. DAU 5884 hydrochloride inhibits methacholine-dependent effects on cell proliferation and muscle contractility .
|
-
-
- HY-P3618
-
|
|
Somatostatin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .
|
-
-
- HY-W008820S1
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d4 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .
|
-
-
- HY-107610
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SR2640 (hydrochloride) is a potent and selective competitive leukotriene D4/leukotriene E4 antagonist. SR2640 can be used for researching the role of leukotrienes in human asthma .
|
-
-
- HY-103283
-
|
GRP(18-27) (porcine)
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
Neuromedin C porcine (GRP, 18-27, porcine) is a bombesin-like neuropeptide that can be obtained from porcine spinal cord. Neuromedin C porcine exhibits a potent contractile activity on rat uterus in the characteristic manner of bombesin. Neuromedin C porcine has research potential for neurological-related diseases .
|
-
-
- HY-16056
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Arbutamine is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine can be used for cardiac stress agent .
|
-
-
- HY-16056A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Arbutamine hydrochloride is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine hydrochloride stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine hydrochloride provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine hydrochloride can be used for cardiac stress agent .
|
-
-
- HY-120648A
-
|
|
Cytochrome P450
|
Cardiovascular Disease
|
|
CAY 10434 dihydrochloride is a potent CYP4A hydroxylase inhibitor. CAY 10434 dihydrochloride improves contractile response to angiotensin II with the maximal contractile response (Emax) 6764 mg .
|
-
-
- HY-160076
-
|
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
APJ receptor agonist 8 (compound 99) is an agonist of APJ receptor. APJ receptor agonist 8 increases the load independent cardiac contractility of isolated perfused rat hearts .
|
-
-
- HY-P3853
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
GR 87389 is a potent NK2 receptor antagonist. GR 87389 antagonized GA 64349-induced smooth muscle strips contractions in a competitive manner in the human detrusor, prostate and prostatic urethra .
|
-
-
- HY-113096
-
|
PGD1
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC50 value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .
|
-
-
- HY-19020
-
|
|
Leukotriene Receptor
|
Cardiovascular Disease
|
|
FK-664 is a leukotriene inhibitor. FK-664 enhances ventricular contractility and shortens the time to peak tension in cardiac cells. FK-664 reduces mean circulating pressure (MCP) in a canine model of heart failure. FK-664 can be used in research on cardiovascular diseases such as heart failure .
|
-
-
- HY-N13747
-
|
|
Myosin
PKC
Calcium Channel
|
Cardiovascular Disease
|
|
Chrysosplenol C is a type of flavonoid compound. Chrysosplenol C selectively activates cardiac myosin ATPase, with its EC50 being 45 µM. Chrysosplenol C enhances the release of intracellular calcium ions by activating protein kinase C (PKC), thereby increasing the contractility of rat ventricular muscle cells. Chrysosplenol C can be used in the research of heart failure .
|
-
-
- HY-103209
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Rec 15/2615 hydrochloride is a potent and selective α-1B adrenoceptor antagonist with Ki values of 1.9 nM, 0.3 nM, 2.6 nM for α1A, α1B, α1D, respectively. Rec 15/2615 hydrochloride modulates vaginal smooth muscle contractility and genital engorgement .
|
-
-
- HY-118960A
-
|
|
ATP Synthase
|
Cardiovascular Disease
|
|
BMS-199264 is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 also enhances the recovery of contractile function following reperfusion .
|
-
-
- HY-10382
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
EXP-6803 is a specific nonpeptide angiotensin II receptor antagonist with antihypertensive activity. EXP-6803 inhibits the contractile response to angiotensin II with a pA2 value of 7.20. EXP-6803 effectively blocks responses to angiotensin I and II while not affecting responses to bradykinin or acetylcholine in guinea pig ileum. EXP-6803 can be used for hypertension research .
|
-
-
- HY-P0084A
-
|
SRIF-14 acetate; Somatostatin-14 acetate
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
Cyclic somatostatin (SRIF-14) acetate is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin acetate is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin acetate inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin acetate can be used for the research of cardiovascular disease .
|
-
-
- HY-106049
-
-
- HY-103296
-
-
- HY-167103A
-
-
- HY-125304
-
|
|
Neurokinin Receptor
|
Endocrinology
|
|
L 363851 is a Neurokinin 2 receptor agonist, and induces the contractile response of tracheal smooth muscle devoid of epithelium (IC50 of 3.2 nM) and phosphoinositide hydrolysis (IC50 of 36 μM).
|
-
- HY-120180
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
BMS-188107 is a calcium antagonist that exerts anti-ischemic effects. BMS-188107 improves postischemic contractile function and reduces lactate dehydrogenase release. BMS-188107 can be utilized in cardiovascular research .
|
-
- HY-W050000R
-
|
|
Drug Metabolite
Reference Standards
Reactive Oxygen Species (ROS)
ERK
p38 MAPK
|
Cardiovascular Disease
Inflammation/Immunology
|
|
OR-1855 (Standard) is an analytical standard of OR-1855 (HY-W050000). This product is intended for research and analytical applications. OR-1855, an active metabolite of Levosimendan (HY-14286), has effect on myometrial contractility. OR-1855 exerts anti-inflammatory effects by inhibiting IL-1β-induced ROS formation and NAD(P)H oxidase-dependent superoxide radical generation in HUVECs. OR-1855 inhibits IL-1β-induced phosphorylation p38 MAPK, ERK1/2, c-Jun and JNK in HUVECs. OR-1855 can be used for the study of inflammation .
|
-
- HY-139801
-
|
CI-907
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Metabolic Disease
|
|
Indolapril hydrochloride (CI-907) is an orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor. Indolapril hydrochloride is highly specific in suppressing the contractile or pressor responses to Angiotensin I. Indolapril hydrochloride is a potent antihypertensive agent .
|
-
- HY-117717
-
|
|
Prostaglandin Receptor
|
Others
|
|
(Rac)-SC-31391, a prostaglandin analog, is a strong activator of the bladder muscle contractility that enhanced twitch responses elicited by field stimulation in the guinea pig detrusor muscle. (Rac)-SC-31391 contracts human bladder muscle through the activation of PGF2α receptors .
|
-
- HY-120648
-
|
|
Cytochrome P450
|
Cardiovascular Disease
|
|
CAY 10434 is a potent CYP4A hydroxylase inhibitor. CAY 10434 improves contractile response to angiotensin II with the maximal contractile response (Emax) 6764 mg .
|
-
- HY-106045
-
|
CI 914 free base
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Imazodan is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan serves also as a peripheral vasodilator .
|
-
- HY-106045A
-
|
CI 914
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Imazodan hydrochloride is the hydrochloride form of Imazodan (HY-106045). Imazodan hydrochloride is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan hydrochloride serves also as a peripheral vasodilator .
|
-
- HY-123721
-
|
AWD-19-166; GS 015
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Tiracizine hydrochloride (AWD-19-166) is a Class I antiarrhythmic drug with activity that reduces myocardial contractile function. Tiracizine hydrochloride was studied in patients with ischemic heart disease, showing its effects on the myocardium. Tiracizine hydrochloride reduces myocardial contractility and may have potential use in the management of heart disease .
|
-
- HY-121306
-
|
Ricainide; LY 135837 free base
|
Sodium Channel
|
Neurological Disease
|
|
Indecainide (Ricainide) is an orally active antiarrhythmic agent. Indecainide can be used in the research of ventricular dysfunction. Indecainide has Na +-channel-blocking activity .
|
-
- HY-19003
-
-
- HY-19003A
-
|
323MHb hydrochloride; Isosulmazole hydrochloride
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Isomazole (323MHb) hydrochloride is a cardiotonic agent. Isomazole hydrochloridei increases the calcium sensitivity in atrial fibers and has a direct effect on contractile proteins .
|
-
- HY-120926
-
|
|
Calcium Channel
|
Others
|
|
BBR 2160 is a compound with cardiac electrophysiological effects and is a dihydropyridine calcium antagonist that can reduce myocardial contractility and action potential duration and has calcium antagonist properties.
|
-
- HY-118833
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
RAC 109 is a local anesthetic. RAC 109 reduces ventricular conduction velocity and myocardial contractility in rabbits in a stereospecific manner (EC50=30 μM) .
|
-
- HY-122409
-
|
|
Others
|
Others
|
|
Cularine is a compound that relaxes guinea pig tracheal and human bronchial smooth muscle, inhibits contraction induced by a variety of contractile agents, and has nonspecific antispasmodic activity, and its activity is structure-related.
|
-
- HY-119926A
-
|
Hydroxylupanine hydrochloride
|
Others
|
Cardiovascular Disease
Neurological Disease
|
|
13-Hydroxylupanine Hydroxylupanine is the typical alkaloid profile of sweet lupins. 13-Hydroxylupanine Hydroxylupanine blocks ganglionic transmission, decreases cardiac contractility and contracts uterine smooth muscle .
|
-
- HY-P1721
-
|
|
Bradykinin Receptor
|
Cardiovascular Disease
|
|
NPC 17731 is a new bradykinin (BK) receptor antagonist. NPC 17731 antagonized both the contractile and relaxant responses caused by BK in longitudinal smooth muscle with IC50 of 23 and 29 nM, respectively .
|
-
- HY-105572
-
|
MC-838 calcium
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Moveltipril calcium (MC-838 calcium) is an orally active angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moveltipril calcium binds via a stable thioester bond and exhibits relative resistance to enzymatic hydrolysis in rat liver homogenate. Moveltipril calcium effectively inhibits ACE extracted from rabbit lung in a concentration-dependent manner. Moveltipril calcium is able to highly specifically inhibit the contractile response to angiotensin-I (AI) in free rat aortic rings and guinea pig ileum preparations, while enhancing the contractile response to calcitonin .
|
-
- HY-123028
-
|
Arginylphenylalaninamide
|
Others
|
Others
|
|
RFamide (Arginylphenylalaninamide) is a neuropeptide that has contraction-inducing activity in gastropod muscles. Its contractile effect is additive with acetylcholine and is regulated by 5-hydroxytryptamine. It can also mobilize intracellular calcium to maintain tension.
|
-
- HY-111018
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
FPL 62129 is an antagonist for calcium channel. FPL 62129 reduces blood pressure and total peripheral resistance, increases the cardiac contractility and cardiac output in anarsthetised beagle model. FPL 62129 also serves as a vasodilator and a direct decelerator .
|
-
- HY-P2150
-
|
|
Somatostatin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .
|
-
- HY-126763
-
|
|
Phosphodiesterase (PDE)
Calcium Channel
|
Others
|
|
ATI22-107 is a dual-pharmacophore compound designed to simultaneously inhibit cardiac phosphodiesterase (PDE-III) and L-type calcium channels (LTCC), with activity that has specific effects on calcium cycling and contractility in cat ventricular myocytes and trabeculae.
|
-
- HY-122364
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Bucumolol hydrochloride is a β-adrenergic receptor antagonist that can slow heart rate (negative chronotropic effect) and reduce cardiac contractility (negative inotropic effect). Bucumolol hydrochloride has antiarrhythmic and local anesthetic activity and can be used in the study of cardiovascular diseases .
|
-
- HY-P4678A
-
|
|
Vasopressin Receptor
|
Neurological Disease
|
|
(Phe2,Orn8)-Oxytocin acetate is a selective V1 vasopressin agonist. (Phe2,Orn8)-Oxytocin acetate induces a sustained contractility of rabbit epididymis with EC50 value of 280 nM .
|
-
- HY-137574
-
|
19(R)-Hydroxy PGE1
|
Prostaglandin Receptor
|
Others
|
|
19(R)-Hydroxy prostaglandin E1 (19(R)-Hydroxy PGE1), the major prostaglandin in primate semen, is an agonist of EP1 and EP3 receptor subtypes and exhibits contractile activity on smooth muscle preparations .
|
-
- HY-W722221
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Colterol acetate is a selective inhibitor of β-adrenergic receptors. Colterol acetate can relax tracheal smooth muscle (primarily acting on β2 receptors), reduce subspastic contractions of tricholoma (acting on β2), and increase contractility of left ventricular papillary muscles (acting on β1) .
|
-
- HY-14257
-
|
|
Potassium Channel
Lactate Dehydrogenase
|
Cardiovascular Disease
|
|
BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects .
|
-
- HY-P1428A
-
|
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
|
|
RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
|
-
- HY-W179151
-
|
|
Dopamine Receptor
|
Inflammation/Immunology
|
|
N-Octanoyl dopamine is superior to dopamine in protecting graft contractile function when administered to the heart transplant recipients from brain-dead donors. N-Octanoyl dopamine inhibits cytokine production in activated T-cells and diminishes MHC-class-II expression as well as adhesion molecules in IFNγ-stimulated endothelial cells .
|
-
- HY-165045
-
|
DG(15:0/15:0/0:0); 1,2-Dipentadecanoin
|
Endogenous Metabolite
|
Others
|
|
1,2-Dipentadecanoyl-rac-glycerol (DG(15:0/15:0/0:0)) is a compound mentioned in the study of the effects of insulin on 1,2-diacylglycerol in rat hearts. Insulin can increase the content of 1,2-diacylglycerol with a specific fatty acid composition in the heart, which may be related to cardiac contractility.
|
-
- HY-130448
-
|
|
Prostaglandin Receptor
ROCK
|
Cardiovascular Disease
|
|
8-iso Prostaglandin F1β is an isoprostane, that exhibits vasoconstrictive effect in neonatal porcine pulmonary arteries, pulmonary veins, and mesenteric arteries. 8-iso Prostaglandin F1β targets TXA2 receptor and exhibits the blood vessel contractile efficacy under the influence of tyrosine kinase and Rho kinase .
|
-
- HY-106761
-
|
|
Calcium Channel
|
Cardiovascular Disease
Others
|
|
Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs .
|
-
- HY-123449A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
MK-761 TFA is an orally effective β2-adrenergic receptor antagonist. MK-761 TFA attenuates positive inotropic effects, reduces arterial pressure, enhances the contractility of papillary muscles in cat hearts, and exerts effects mediated by catecholamine release. MK-761 TFA can be used in the research of hypertension .
|
-
- HY-115381
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Lipoxin A5 is an eicosapentaenoic acid derived from pig white blood cells. Lipoxin A5 slowly contracted the guinea pig lung parenchymal strips with a contractile force similar to that of LXA4 and LXB4.2, but LXA5 did not have the vasodilating effect on the aortic smooth muscle shown by LXA4 and LXB4.2 .
|
-
- HY-123449
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
MK-761 free base is an orally effective β2-adrenergic receptor antagonist. MK-761 free base attenuates positive inotropic effects, reduces arterial pressure, enhances the contractility of papillary muscles in cat hearts, and exerts effects mediated by catecholamine release. MK-761 free base can be used in the research of hypertension .
|
-
- HY-123459
-
|
ABT-232; NS-49; PNO-49B
|
Adrenergic Receptor
|
Endocrinology
|
|
Garomefrine hydrochlorid (ABT-232) is an α1A-adrenergic agonist with the potential to inhibit urinary incontinence. Garomefrine hydrochlorid showed the greatest contractility in pig nasal mucosal vessels. The biological activity of Garomefrine hydrochlorid has been shown to give it a competitive advantage compared to other drugs. The potency of Garomefrine hydrochlorid makes it a valuable research object in related research .
|
-
- HY-13338A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
(S)-Mabuterol is a selective β2 adrenoreceptor agonist that demonstrates blood pressure reduction and increased heart rate and contractile force in animal models.
|
-
- HY-113727
-
-
- HY-N8421
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
Tabernanthine is a negative chronotropic and negative inotropic agent that selectively acts on sinoatrial node receptors, regulating heart rhythm and myocardial contractility. Tabernanthine exhibits atropine resistance and direct non-cholinergic binding properties, acting directly on the sinoatrial node rather than relying on vagal nerve or cholinergic pathways to exert its key activity of slowing heart rate and weakening myocardial contractility. Tabernanthine is useful in cardiovascular pharmacology research, particularly in the areas of sinoatrial node function regulation, mechanisms related to bradycardia, and studies of cardiac receptor subtype differences .
|
-
- HY-W411193
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
Pincainide is a calcium channel inhibitor. Pincainide inhibits voltage-gated calcium channel-mediated calcium influx in smooth muscle. Pincainide inhibits norepinephrine- and high potassium-induced contractile responses. Pincainide can be used in the research of heart diseases .
|
-
- HY-19185
-
|
|
Potassium Channel
|
Endocrinology
|
|
ZD-2767 is a selective ATP-sensitive potassium channel agonist. ZD-276 reduces cell membrane excitability and contractility by activating KATP channels in bladder smooth muscle. ZD-2767 is promising for research of overactive bladder .
|
-
- HY-W008820S2
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d2 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .
|
-
- HY-19091
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
ICI-170777 is an orally active cardiotonic agent. ICI-170777 enhances cardiac contractility and induces arteriovenous dilation in animal models of congestive heart failure. ICI-170777 can be used in research on cardiovascular and cerebrovascular diseases such as heart failure .
|
-
- HY-107610R
-
|
|
Reference Standards
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SR2640 hydrochloride (Standard) is the analytical standard of SR2640 (hydrochloride) (HY-107610). This product is intended for research and analytical applications. SR2640 (hydrochloride) is a potent and selective competitive leukotriene D4/leukotriene E4 antagonist. SR2640 can be used for researching the role of leukotrienes in human asthma .
|
-
- HY-P1994A
-
|
|
Cholecystokinin Receptor
|
Neurological Disease
|
|
JMV 170, a CCK derivative, is a selective CCK-B agonist. JMV 170 binds to the CCK-B receptor with a 10-fold higher affinity than to the CCK-A receptor. JMV 170 shows contractile effects on pig smooth muscle cells with an EC50 of 9 pmol/L .
|
-
- HY-182252
-
|
|
Na+/Ca2+ Exchanger
|
Cardiovascular Disease
|
|
SAR296968 is a Na +/Ca 2+ exchanger (NCX) subtype inhibitor with an IC50 value of 74 nM against hNCX1. SAR296968 inhibits both forward and reverse modes of NCX current. SAR296968 enhances cardiac contractility and stroke volume. SAR296968 exerts antiarrhythmic effects. SAR296968 is applicable to research related to heart failure .
|
-
- HY-W700354
-
|
|
Calcium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
(S)-(-)-Felodipine is a S-enantiomer of Felodipine. (S)-(-)-Felodipine is an antihypertensive agent. Felodipine is a 1,4-dihydropyridine derivative and a vasoselective calcium antagonist. Felodipine can prevent the activation of the vascular effector cells and interfere with the contractile process in vitro. Felodipine lowers mean arterial blood pressure by 20% in dog model. (S)-(-)-Felodipine shows high metabolic rate in rat and dog liver microsomes .
|
-
- HY-19066
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
KW-3407 is an antiarrhythmic agent. KW-3407 can inhibit two-stage (24 and 48 h) coronary ligation-, digitalis- and adrenaline-induced spontaneously occurring arrhythmias with IC50 values of 18.1, 14.4, 18.3 and 21.4 μg/mL. KW-3407 can decrease the sinoatrial rate and contractile force, and increase the coronary blood flow and AV conduction times .
|
-
- HY-P0084
-
|
SRIF-14; Somatostatin-14
|
Endogenous Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
|
-
- HY-113096S
-
|
PGD1-d4
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
Prostaglandin D1-d4 (PGD1-d4) is deuterium labeled Prostaglandin D1. Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC50 value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .
|
-
- HY-121467S1
-
|
Z-338 free base-d4; YM443 free base-d4
|
Isotope-Labeled Compounds
Cholinesterase (ChE)
|
Metabolic Disease
Inflammation/Immunology
|
|
Acotiamide-d4 (Z-338 (free base)-d4) is deuterium labeled Acotiamide. Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
|
-
- HY-106058
-
|
|
Cathepsin
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
NCO-700 is a dual cathepsin B and calcium-activated neutral protease (CANP) inhibitor with IC50 values of 0.8 and 46 μM, respectively. NCO-700 reduces the degradation of myocardial fibrin by inhibiting protease activity. NCO-700 also has inhibitory effects on hormone-independent tumor cells, such as prostate cancer cells, and induces apoptosis. NCO-700 can be used to study myocardial ischemia and refractory hormone-independent tumors .
|
-
- HY-105431
-
|
|
Na+/K+ ATPase
|
Cardiovascular Disease
|
|
ASI-222 is an aminosugar cardiac glycoside. ASI-222 can inhibit Na+/K+ ATPase and show positive inotropic effect. ASI-222 can be used for the research of cardiovascular disease .
|
-
- HY-A0252A
-
|
|
Adrenergic Receptor
|
Cancer
|
|
Bupranolol hydrochloride is a non-selective β-adrenergic blocker with potent membrane stabilizing activity. Bupranolol hydrochloride is able to significantly modulate the contractile activity of the non-pregnant human uterus. Bupranolol hydrochloride showed significant effects on spontaneous uterine contractions in an in vitro study in patients with ovarian cancer. Bupranolol hydrochloride is similar in potency to propranolol, another β-adrenergic blocker. Bupranolol hydrochloride is rapidly and completely absorbed in vivo, and its major metabolite is carboxybupranolol .
|
-
- HY-150039
-
|
|
G Protein-coupled Receptor Kinase (GRK)
|
Cardiovascular Disease
|
|
CCG-271423 is a potent and selective GRK5 inhibitor with IC50 values of 0.0021 μM and 44 μM for GRK5 and GRK2, respectively. CCG-271423 inhibits cardiomyocyte contractility and decreases in Ca 2+ transience . CCG-271423 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-B0763S1
-
|
|
Isotope-Labeled Compounds
Phosphodiesterase (PDE)
|
Inflammation/Immunology
Cancer
|
|
Ibudilast-d7 is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
|
-
- HY-B1116A
-
|
(-)-Metaraminol; (-)-erythro-Metaraminol; (-)-m-Hydroxynorephedrine
|
Adrenergic Receptor
|
Neurological Disease
|
|
Metaraminol ((-)-Metaraminol) is a sympathomimetic compound with activity that acts primarily at alpha-1 adrenergic receptors. Metaraminol is used to inhibit hypotension due to vasodilation, particularly in critically ill patients who do not respond well to volume resuscitation. Metaraminol may also be used as an adjunct to help improve cardiac contractility. The use of metaraminol may be supported by less evidence, but its effectiveness in specific situations remains of interest .
|
-
- HY-B0763R
-
|
KC-404 (Standard); AV-411 (Standard); MN-166 (Standard)
|
Reference Standards
Phosphodiesterase (PDE)
|
Inflammation/Immunology
Cancer
|
|
Ibudilast (Standard) is the analytical standard of Ibudilast. This product is intended for research and analytical applications. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
|
-
- HY-Y0047
-
|
Picolamine; 3-Pyridinemethanamine; Pyridin-3-ylmethanamine
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
3-Picolylamine is a primary amine compound containing a pyridine ring structure. 3-Picolylamine inhibits histaminase (diamine oxidase) activity in pig kidneys. 3-Picolylamine significantly enhances the contractile response of isolated guinea pig ileum to Histamine (HY-B1204). 3-Picolylamine can be used to study histamine-related physiological mechanisms or allergic diseases (such as histamine-mediated inflammatory responses) .
|
-
- HY-B0763S
-
|
|
Isotope-Labeled Compounds
Phosphodiesterase (PDE)
|
Inflammation/Immunology
Cancer
|
|
Ibudilast-d3 (KC-404-d3) is the deuterium labeled Ibudilast. Ibudilast (KC-404) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
|
-
- HY-116326
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
BayCysLT2, an isophthalic acid derivative, is a selective and potent cysteinyl leukotriene 2 (CysLT2) receptor antagonist with an IC50 value of 53 nM. BayCysLT2 inhibits calcium mobilization induced by leukotriene D4 in HEK293 cells expressing human CysLT2 receptors. BayCysLT2 reverses LTC4-induced increases in coronary artery perfusion pressure and decreases in contractility in isolated perfused guinea pig hearts .
|
-
- HY-B2155R
-
|
|
Reference Standards
Cholinesterase (ChE)
|
Metabolic Disease
Inflammation/Immunology
|
|
Acotiamide (monohydrochloride trihydrate) (Standard) is the analytical standard of Acotiamide (monohydrochloride trihydrate). This product is intended for research and analytical applications. Acotiamide monohydrochloride trihydrate is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC50 of 1.79 μM. Acotiamide monohydrochloride trihydrate can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide monohydrochloride trihydrate has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
|
-
- HY-178082
-
|
|
Others
|
Cardiovascular Disease
|
|
MK-251 is an orally active anti-arrhythmic agent. MK-251 prevents or modifies ventricular arrhythmias induced in dogs and baboons by tetrafluorethylbutylamine. MK-251 antagonizes the arrhythmias caused by Digoxin (HY-B1049) in cats. MK-251 at effective doses has little effect on basic cardiovascular parameters such as blood pressure, cardiac output, myocardial contractility and ventricular conduction, thus demonstrating its unique advantages .
|
-
- HY-B0763S2
-
|
KC-404-d7-1; AV-411-d7-1; MN-166-d7-1
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Ibudilast-d7-1 is the deuterium labeled Ibudilast . Ibudilast (KC-404;AV-411;MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
|
-
- HY-117181
-
|
|
Phosphodiesterase (PDE)
Adrenergic Receptor
|
Cardiovascular Disease
|
|
UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure .
|
-
- HY-180376
-
|
|
Neurokinin Receptor
|
Inflammation/Immunology
|
|
TAC 363 is a selective tachykinin NK-2 receptor antagonist. TAC 363 shows a rightward shift in the contractile response curve induced by Neurokinin A (HY-P0197) with a pA2 of 9.82. TAC 363 has a weak antagonistic effect on NK-1 receptors. TAC 363 can inhibit Neurokinin A-induced bronchoconstriction in guinea pigs with an ED50 of 0.3 mg/kg. TAC 363 can be used for the research of bronchial asthma .
|
-
- HY-19279A
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
JTH-601 Free base is a novel alpha1-adrenoceptor antagonist that exhibits potent activity in inhibiting phenylephrine-induced contractions in lower urinary tract tissues. JTH-601 Free base competitively antagonizes alpha1-adrenoceptor-mediated contractile responses, demonstrating greater potency than prazosin or tamsulosin. JTH-601 Free base is anticipated to be effective in treating urinary outlet obstruction associated with benign prostatic hyperplasia.
|
-
- HY-N2071
-
-
- HY-P4160
-
|
THG113.31; ILGHXDYK
|
Prostaglandin Receptor
|
Endocrinology
|
|
PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca 2+-dependent large-conductance K +-channel in human myometrial cells .
|
-
- HY-182599
-
|
|
Calcium Channel
mAChR
|
Neurological Disease
|
|
RCC-36 hydrochloride is an L-type calcium channel inhibitor and competitive muscarinic receptor antagonist. RCC-36 hydrochloride inhibits L-type calcium currents in voltage- and concentration-dependent fashion with no effect on cardiac K + currents. RCC-36 hydrochloride suppresses maximum acetylcholine-induced contractile responses, inhibits detrusor muscle contractions induced by potassium chloride, calcium chloride, and electric field stimulation, including atropine-resistant contractions. RCC-36 hydrochloride can be used for the research of urinary frequency, urinary incontinence, and bladder overactivity .
|
-
- HY-N2071R
-
|
(+)-Cedrol (Standard); α-Cedrol (Standard)
|
Reference Standards
Cytochrome P450
Fungal
Apoptosis
Caspase
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Cedrol (Standard) is the analytical standard of Cedrol. This product is intended for research and analytical applications. Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.
|
-
- HY-P2601A
-
|
|
CGRP Receptor
|
Others
|
|
Tyr-α-CGRP (human) TFA is an N-terminally extended human α-CGRP analog. Tyr-α-CGRP (human) TFA can bind to membrane preparations from rat brain and spleen with IC50 values of 0.2 nM and 0.5 nM, respectively, and induce positive chronotropic and inotropic effects in isolated guinea pig right and left atria with EC50 values of 282 nM and 74 nM, respectively. Tyr-α-CGRP (human) TFA also inhibits contractile responses in rat vas deferens with an EC50 value of 1.9 nM .
|
-
- HY-123659
-
|
|
Na+/H+ Exchanger (NHE)
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
KR-33028 is a selective NHE1 inhibitor. KR-33028 reduces hypoxia-induced necrosis and apoptosis in H9c2 cells. KR-33028 inhibits hypoxia-induced increases in cytoplasmic and mitochondrial Ca 2+ levels and cytochrome c release. KR-33028 improves cardiac contractility, reduces lactate dehydrogenase release, and increases tissue ATP, creatine phosphate, and glycogen levels. KR-33028 can be used in research on cancers such as cardioblastoma and cardiovascular diseases such as ischemic stroke .
|
-
- HY-175603
-
|
|
Amine N-methyltransferase
|
Cancer
|
|
NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 <10 nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research, such as ovarian cancer, breast cancer, colon cancer .
|
-
- HY-B0204B
-
|
(-)-UD-CG115
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
(-)-Pimobedan is an isomer of pimobedan. It has the property of stereoselective partitioning or distribution into erythrocytes. The clearance of (-)-pimobedan from erythrocytes is significantly lower than that of (+)-pimobedan, which is entirely due to its stereoselective distribution into erythrocytes. This stereoselective property of (-)-pimobedan may explain the phenomenon previously reported that it produces a 1.5-fold greater contractile force than the (+)-isomer in detergent-treated myocardial specimens of guinea pigs and dogs. These properties suggest that (-)-pimobedan may have unique advantages in terms of in vivo distribution and pharmacological action, which may have important implications for its clinical use.
|
-
- HY-121998
-
|
|
Aurora Kinase
|
Others
|
|
Binucleine 2 is an isoform-specific and ATP-competitive inhibitor of Drosophila Aurora B kinase (Ki=0.36 μM), a kinase involved in cell division. It is specific for Drosophila Aurora B kinase, inhibiting it in a dose-dependent manner, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 μM. Binucleine 2 induces mitotic and cytokinesis defects in Drosophila Kc167 cells. It prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 μM but does not affect ring ingression, suggesting that Aurora B kinase activity is not required for that step.
|
-
- HY-A0144A
-
|
|
Adrenergic Receptor
AMPK
Akt
|
Cardiovascular Disease
|
|
Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
|
-
- HY-A0144
-
|
|
Adrenergic Receptor
AMPK
Akt
|
Cardiovascular Disease
|
|
Etilefrine is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
|
-
- HY-137608
-
|
UDP-β-S
|
P2Y Receptor
DNA/RNA Synthesis
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Uridine 5'-O-thiodiphosphate (UDP-β-S) is a P2Y6 receptor agonist with an EC50 of 25 nM. Uridine 5'-O-thiodiphosphate resists degradation by extracellular nucleotidases and stimulates the accumulation of inositol phosphates. Uridine 5'-O-thiodiphosphate stimulates contractile responses in endothelium-denuded rat mesenteric arteries. As a mitogen, Uridine 5'-O-thiodiphosphate stimulates DNA synthesis, [ 3H] thymidine incorporation, protein synthesis, [ 3H]leucine incorporation, and increases the number of vascular smooth muscle cells. Uridine 5'-O-thiodiphosphate can be used in the research of cardiovascular diseases such as atherosclerosis .
|
-
- HY-W005255
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .
|
-
- HY-137608A
-
|
UDP-β-S trisodium
|
P2Y Receptor
DNA/RNA Synthesis
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Uridine 5'-O-thiodiphosphate trisodium (UDP-β-S trisodium) is a P2Y6 receptor agonist with an EC50 of 25 nM. Uridine 5'-O-thiodiphosphate trisodium resists degradation by extracellular nucleotidases and stimulates the accumulation of inositol phosphates. Uridine 5'-O-thiodiphosphate trisodium stimulates contractile responses in endothelium-denuded rat mesenteric arteries. As a mitogen, Uridine 5'-O-thiodiphosphate trisodium stimulates DNA synthesis, [ 3H] thymidine incorporation, protein synthesis, [ 3H]leucine incorporation, and increases the number of vascular smooth muscle cells. Uridine 5'-O-thiodiphosphate trisodium can be used in the research of cardiovascular diseases such as atherosclerosis .
|
-
- HY-P2141
-
|
TRV027
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
|
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
|
-
- HY-A0144R
-
|
|
Adrenergic Receptor
AMPK
Akt
Reference Standards
|
Cardiovascular Disease
|
|
Etilefrine (Standard) is the analytical standard of Etilefrine. This product is intended for research and analytical applications. Etilefrine is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
|
-
- HY-A0144AR
-
|
|
Reference Standards
AMPK
Adrenergic Receptor
Akt
|
Cardiovascular Disease
|
|
Etilefrine hydrochloride (Standard) is the analytical standard of Etilefrine hydrochloride (HY-A0144A). This product is intended for research and analytical applications. Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
|
-
- HY-159821
-
|
CK-4021586; CK-586
|
Myosin
|
Cardiovascular Disease
|
|
Ulacamten (CK-4021586; CK-586) is an orally active cardiac myosin inhibitor and an inhibitor of the double-headed cardiac heavy meromyosin (HMM)ATPase (excluding single-headed myosin subfragment-1), with an EC50 of 2.9 μM. Ulacamten regulates cardiac myosin, reduces excessive myocardial contractility, and alleviates left ventricular outflow tract obstruction. Ulacamten increases the left ventricular short-axis systolic internal diameter, inhibits dobutamine-induced exacerbation of obstruction, and exerts only a mild reducing effect on left ventricular systolic function. Ulacamten also inhibits the fractional shortening of the short axis without altering calcium transients. Ulacamten shows good safety and tolerability in purpose-bred cats with naturally occurring obstructive hypertrophic cardiomyopathy .
|
-
- HY-P2141A
-
|
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
|
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .
|
-
- HY-181774
-
|
|
Phosphodiesterase (PDE)
|
Endocrinology
|
|
PDE4/5-IN-1 is a selective phosphodiesterase 4/5 (PDE4/5) dual inhibitor. PDE4/5-IN-1 functionally inhibits PDE5, PDE4B2, and PDE4D2 activity. PDE4/5-IN-1 relaxes isolated rat prostate tissue, enhances nitric oxide-induced relaxation in isolated rat prostate tissue, and reduces alpha-1 adrenoceptor-mediated contractile responses in isolated rat prostate tissue. PDE4/5-IN-1 inhibits proliferation of human hyperplastic prostate cells. PDE4/5-IN-1 can be used for the research of benign prostatic hyperplasia .
|
-
- HY-W008820R
-
|
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid (Standard) is the analytical standard of Glutaric acid. This product is intended for research and analytical applications. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .
In Vitro: Glutaric acid (GA) at concentrations of 1 and 2 mM is able to reduce TRAP measurement by up to 28% in a dose-dependent manner (β=0.77; P<0.001). Furthermore, a significantly inverse correlation is also verified between chemiluminescence and TRAP (β=0.81; P<0.001). Glutaric acid does not alter the activities of Cat and SOD, but strongly inhibits (up to 46%) the activity of GPx even at the lower concentration used (0.5 mM). It is observed that the metabolite inhibits this activity in a dose-dependent manner at concentrations as low as 0.05 mM .
|
-
- HY-D1056A2
-
|
LPS, from Escherichia coli (O127:B8)
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Lipopolysaccharides, from E. coli O127:B8 (LPS, from Escherichia coli (O127:B8)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O127:B8) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O127:B8 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O127:B8 activate TLR-4 in immune cells, can induce inflammatory responses and ileal contractility, and can be used to construct intestinal inflammation models .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
|
-
- HY-128061
-
|
|
Phospholipase
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
|
|
CDIBA is a cytosolic phospholipase A2 (cPLA2) inhibitor. CDIBA inhibits the activation of cPLA2 in rat diaphragm tissue. CDIBA reduces the level of mitochondrial reactive oxygen species in rat diaphragm tissue after prolonged mechanical ventilation. CDIBA attenuates protein degradation, muscle atrophy and decreased muscle strength in the diaphragm of rats after prolonged mechanical ventilation. CDIBA can be used in studies related to ventilator-induced diaphragmatic dysfunction .
|
-
- HY-103192
-
|
RMI12330A
|
Adenylate Cyclase
Potassium Channel
|
Neurological Disease
Cancer
|
|
MDL12330A (RMI12330A) is an adenylyl cyclases inhibitor. MDL12330A can inhibit KV channels, increases insulin secretion and Ca 2+ levels. MDL12330A accentuates contractions in uterine rings and inhibits cardiac functions. MDL12330A can be used for the research of endocrinology, metabolic and cardiovascular disease .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D1056A2
-
|
LPS, from Escherichia coli (O127:B8)
|
Biochemical Assay Reagents
|
Lipopolysaccharides, from E. coli O127:B8 (LPS, from Escherichia coli (O127:B8)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O127:B8) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O127:B8 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O127:B8 activate TLR-4 in immune cells, can induce inflammatory responses and ileal contractility, and can be used to construct intestinal inflammation models .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
|
-
- HY-A0144A
-
|
|
Biochemical Assay Reagents
|
|
Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
|
-
- HY-A0144AR
-
|
|
Biochemical Assay Reagents
|
|
Etilefrine hydrochloride (Standard) is the analytical standard of Etilefrine hydrochloride (HY-A0144A). This product is intended for research and analytical applications. Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0084
-
|
SRIF-14; Somatostatin-14
|
Endogenous Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
|
-
- HY-W016733
-
|
H-D-Cit-OH
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
D-Citrulline (H-D-Cit-OH) is a stereoisomer of L-citrulline (HY-N0391). D-Citrulline significantly attenuates polymorphonuclear leukocyte (PMN)-induced cardiac contractile dysfunction in the isolated perfused rat heart subjected to ischemia/reperfusion via a non-NO-mediated mechanism .
|
-
- HY-P2141
-
|
TRV027
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
|
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
|
-
- HY-P10655
-
|
|
Proton Pump
Calcium Channel
|
Cardiovascular Disease
|
|
Caloxin 1C2 is a specific PMCA (plasma-membrane Ca 2+-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The Ki values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca 2+ transfer. Caloxin 1C2 affects coronary contractility .
|
-
- HY-103291
-
|
|
Bradykinin Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Sar-[D-Phe8]-des-Arg9-Bradykinin is a agonist of B1 receptor. Sar-[D-Phe8]-des-Arg9-Bradykinin selectively amplifies the contractile response when incubation with human recombinant interleukin-1 β (IL-1 β) in rabbit aortic rings .
|
-
- HY-P4678
-
|
|
Vasopressin Receptor
|
Neurological Disease
|
|
(Phe2,Orn8)-Oxytocin is a selective V1 vasopressin agonist. (Phe2,Orn8)-Oxytocin induces a sustained contractility of rabbit epididymis with EC50 value of 280 nM .
|
-
- HY-P4160
-
|
THG113.31; ILGHXDYK
|
Prostaglandin Receptor
|
Endocrinology
|
|
PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca 2+-dependent large-conductance K +-channel in human myometrial cells .
|
-
- HY-P2141A
-
|
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
|
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .
|
-
- HY-P3591
-
-
- HY-P3618
-
|
|
Somatostatin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .
|
-
- HY-103283
-
|
GRP(18-27) (porcine)
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
Neuromedin C porcine (GRP, 18-27, porcine) is a bombesin-like neuropeptide that can be obtained from porcine spinal cord. Neuromedin C porcine exhibits a potent contractile activity on rat uterus in the characteristic manner of bombesin. Neuromedin C porcine has research potential for neurological-related diseases .
|
-
- HY-P3853
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
GR 87389 is a potent NK2 receptor antagonist. GR 87389 antagonized GA 64349-induced smooth muscle strips contractions in a competitive manner in the human detrusor, prostate and prostatic urethra .
|
-
- HY-P0084A
-
|
SRIF-14 acetate; Somatostatin-14 acetate
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
Cyclic somatostatin (SRIF-14) acetate is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin acetate is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin acetate inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin acetate can be used for the research of cardiovascular disease .
|
-
- HY-P1721
-
|
|
Bradykinin Receptor
|
Cardiovascular Disease
|
|
NPC 17731 is a new bradykinin (BK) receptor antagonist. NPC 17731 antagonized both the contractile and relaxant responses caused by BK in longitudinal smooth muscle with IC50 of 23 and 29 nM, respectively .
|
-
- HY-P2150
-
|
|
Somatostatin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .
|
-
- HY-P4678A
-
|
|
Vasopressin Receptor
|
Neurological Disease
|
|
(Phe2,Orn8)-Oxytocin acetate is a selective V1 vasopressin agonist. (Phe2,Orn8)-Oxytocin acetate induces a sustained contractility of rabbit epididymis with EC50 value of 280 nM .
|
-
- HY-P1428A
-
|
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
|
|
RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
|
-
- HY-P2601A
-
|
|
CGRP Receptor
|
Others
|
|
Tyr-α-CGRP (human) TFA is an N-terminally extended human α-CGRP analog. Tyr-α-CGRP (human) TFA can bind to membrane preparations from rat brain and spleen with IC50 values of 0.2 nM and 0.5 nM, respectively, and induce positive chronotropic and inotropic effects in isolated guinea pig right and left atria with EC50 values of 282 nM and 74 nM, respectively. Tyr-α-CGRP (human) TFA also inhibits contractile responses in rat vas deferens with an EC50 value of 1.9 nM .
|
-
- HY-P10528
-
|
|
Peptides
|
Others
|
|
Echinotocin is a neuropeptide found in sea urchins that has muscle contractile activity. Echinotocin can cause contractions of the tube feet and esophagus of sea urchins. Echinotocin can be used to study the role of neuropeptides in invertebrate physiology and behavior .
|
-
- HY-P1994A
-
|
|
Cholecystokinin Receptor
|
Neurological Disease
|
|
JMV 170, a CCK derivative, is a selective CCK-B agonist. JMV 170 binds to the CCK-B receptor with a 10-fold higher affinity than to the CCK-A receptor. JMV 170 shows contractile effects on pig smooth muscle cells with an EC50 of 9 pmol/L .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-W008820
-
-
-
- HY-W005255
-
-
-
- HY-136933
-
-
-
- HY-N2071
-
-
-
- HY-B1233
-
-
-
- HY-N9141
-
-
-
- HY-W008820R
-
|
|
Structural Classification
Microorganisms
Ketones, Aldehydes, Acids
Disease markers
Endocrine diseases
Nervous System Disorder
Endogenous metabolite
Source Classification
|
Reference Standards
Endogenous Metabolite
|
|
Glutaric acid (Standard) is the analytical standard of Glutaric acid. This product is intended for research and analytical applications. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .
In Vitro: Glutaric acid (GA) at concentrations of 1 and 2 mM is able to reduce TRAP measurement by up to 28% in a dose-dependent manner (β=0.77; P<0.001). Furthermore, a significantly inverse correlation is also verified between chemiluminescence and TRAP (β=0.81; P<0.001). Glutaric acid does not alter the activities of Cat and SOD, but strongly inhibits (up to 46%) the activity of GPx even at the lower concentration used (0.5 mM). It is observed that the metabolite inhibits this activity in a dose-dependent manner at concentrations as low as 0.05 mM .
|
-
-
- HY-N13747
-
-
-
- HY-119926A
-
-
-
- HY-N2071R
-
-
-
- HY-N8421
-
|
|
Apocynaceae
Structural Classification
Alkaloids
Plants
Indole Alkaloids
Tabernanthe iboga Baill.
Source Classification
|
Potassium Channel
|
|
Tabernanthine is a negative chronotropic and negative inotropic agent that selectively acts on sinoatrial node receptors, regulating heart rhythm and myocardial contractility. Tabernanthine exhibits atropine resistance and direct non-cholinergic binding properties, acting directly on the sinoatrial node rather than relying on vagal nerve or cholinergic pathways to exert its key activity of slowing heart rate and weakening myocardial contractility. Tabernanthine is useful in cardiovascular pharmacology research, particularly in the areas of sinoatrial node function regulation, mechanisms related to bradycardia, and studies of cardiac receptor subtype differences .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
| Cat. No. |
Product Name |
|
Classification |
-
- HY-150039
-
|
|
|
Alkynes
|
|
CCG-271423 is a potent and selective GRK5 inhibitor with IC50 values of 0.0021 μM and 44 μM for GRK5 and GRK2, respectively. CCG-271423 inhibits cardiomyocyte contractility and decreases in Ca 2+ transience . CCG-271423 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: